United Therapeutics Corp
NASDAQ:UTHR 1:49:44 PM EDT
| Market Cap (Intraday) | 7.43B |
| Current PE | 14.44 |
| Forward PE | 13.07 |
| 2yr Forward PE | N/A |
| 10-Day MA | $170.43 |
| 50-Day MA | $162.96 |
| 200-Day MA | $129.18 |
United Therapeutics Corp. Stock, NASDAQ:UTHR
1040 Spring Street, Silver Spring, Maryland 20910
United States of America
Phone: +1.301.608.9292
Number of Employees: 920
Description
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.